PT  - JOURNAL ARTICLE
AU  - Bauman, Jonathan N.
AU  - Doran, Angela C.
AU  - King-Ahmad, Amanda
AU  - Sharma, Raman
AU  - Walker, Gregory S.
AU  - Lin, Jian
AU  - Lin, Tsung H
AU  - Telliez, Jean-Baptiste
AU  - Tripathy, Sakambari
AU  - Goosen, Theunis C.
AU  - Banfield, Christopher
AU  - Malhotra, Bimal K
AU  - Dowty, Martin E
TI  - <strong>The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans</strong>
AID  - 10.1124/dmd.122.000829
DP  - 2022 Jan 01
TA  - Drug Metabolism and Disposition
PG  - DMD-AR-2022-000829
4099  - http://dmd.aspetjournals.org/content/early/2022/06/14/dmd.122.000829.short
4100  - http://dmd.aspetjournals.org/content/early/2022/06/14/dmd.122.000829.full
AB  - Abrocitinib is an oral once-daily Janus kinase 1 selective inhibitor being developed for the treatment of moderate-to-severe atopic dermatitis. This study examined the disposition of abrocitinib in male participants following oral and intravenous administration using accelerator mass spectroscopy methodology to estimate pharmacokinetic parameters and characterize metabolite profiles. The results indicated abrocitinib had a systemic clearance of 64.2 L/h, a steady state volume of distribution of 100 L, extent of absorption >90%, time to maximum plasma concentration of ≈0.5 hour, and absolute oral bioavailability of 60%. The half-lifeof both abrocitinib and total radioactivity was similar with no indication of metabolite accumulation. Abrocitinib was the main circulating drug species in plasma (≈26%) with 3 major mono-hydroxylated metabolites (M1, M2, and M4) at >10%. Oxidative metabolism was the primary route of elimination for abrocitinib with the greatest disposition of radioactivity shown in the urine (≈85%). In vitro phenotyping indicated abrocitinib cytochrome P450 fraction of metabolism assignments of 0.53 for CYP2C19, 0.30 for CYP2C9, 0.11 for CYP3A4, and ≈0.06 for CYP2B6. The principal systemic metabolites M1, M2, and M4 were primarily cleared renally. Abrocitinib, M1, and M2 showed pharmacology with similar Janus kinase 1 selectivity, whereas M4 was inactive. Significance Statement This study provides a detailed understanding of the disposition and metabolism of abrocitinib, a JAK inhibitor for atopic dermatitis, in humans, as well as characterization of clearance pathways and pharmacokinetics of abrocitinib and its metabolites.